Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 6/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6310478 | 0.94 | KMT2A (0.38) | KMT2ARAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL6309523 | 0.79 | MEN1 (0.43) | KMT2ARAB9ASMN1; SMN2NPC1TSHR | |
| SCHEMBL6304649 | 0.78 | HTT (0.47) | KMT2ASMN1; SMN2ALDH1A1TSHRMAPT | |
| SCHEMBL6309856 | 0.77 | RAB9A (0.36) | KMT2ARAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL6303010 | 0.77 | RAB9A (0.36) | KMT2ARAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL6305014 | 0.77 | RAB9A (0.36) | KMT2ARAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL6305575 | 0.77 | TYK2 (0.40) | KMT2AKDM4E | |
| SCHEMBL6833400 | 0.77 | TRPV4 (0.35) | KMT2ARAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL6302519 | 0.76 | ALDH1A1 (0.32) | RAB9AALDH1A1NPC1 | |
| SCHEMBL6310229 | 0.75 | KMT2A (0.36) | KMT2ARAB9ASMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949562-B2 | Heterocyclic compounds as ligands of the GABAA receptor | NEUROGEN CORPORATION (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | disclosed |
| US-6653471-B2 | Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction | NEUROGEN CORPORATION | 2003-11-25 | — | — | US | disclosed |
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | PFIZER INC | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | KMT2A 2120/4885RAB9A 962/4885SMN1; SMN2 3794/4885 |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | KMT2A 2120/4885RAB9A 962/4885SMN1; SMN2 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.